Telomir Pharmaceuticals Enters Material Agreement with 03 Life Sciences
Ticker: TELO · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1971532
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Telomir Pharma just signed a big deal with 03 Life Sciences, locking in a new financial obligation.
AI Summary
On September 24, 2024, Telomir Pharmaceuticals, Inc. entered into a Material Definitive Agreement with 03 Life Sciences. This agreement involves a direct financial obligation for Telomir Pharmaceuticals, Inc. The filing was made on September 27, 2024.
Why It Matters
This filing indicates a significant new financial commitment or partnership for Telomir Pharmaceuticals, which could impact its future operations and financial standing.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and financial obligations can introduce new risks related to performance, funding, and market conditions.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- 03 Life Sciences (company) — Counterparty to agreement
- September 24, 2024 (date) — Date of earliest event reported
- September 27, 2024 (date) — Date of report
FAQ
What is the nature of the Material Definitive Agreement between Telomir Pharmaceuticals and 03 Life Sciences?
The filing states that Telomir Pharmaceuticals, Inc. entered into a Material Definitive Agreement with 03 Life Sciences, which constitutes a direct financial obligation for Telomir Pharmaceuticals, Inc.
When did the earliest event reported in this 8-K filing occur?
The earliest event reported occurred on September 24, 2024.
What is the filing date of this 8-K report?
This 8-K report was filed on September 27, 2024.
What is Telomir Pharmaceuticals, Inc.'s state of incorporation and IRS number?
Telomir Pharmaceuticals, Inc. is incorporated in Florida and its IRS Employer Identification No. is 87-2606031.
What is the principal executive office address for Telomir Pharmaceuticals, Inc.?
The principal executive offices are located at 100 SE 2nd St, Suite 2000 #1009, Miami, FL 33131.
Filing Stats: 1,057 words · 4 min read · ~4 pages · Grade level 12.5 · Accepted 2024-09-27 16:15:19
Key Financial Figures
- $5,000,000 — gregate amount of Five Million Dollars ($5,000,000). As of the date of this Current Report
Filing Documents
- form8-k.htm (8-K) — 57KB
- ex10-1.htm (EX-10.1) — 50KB
- 0001493152-24-038530.txt ( ) — 296KB
- telo-20240927.xsd (EX-101.SCH) — 3KB
- telo-20240927_lab.xml (EX-101.LAB) — 33KB
- telo-20240927_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Date: September 27, 2024 By: /s/ Erez Aminov Erez Aminov Chief Executive Officer